Welcome to our dedicated page for WEST PHARMACEUTICAL SERVICES SEC filings (Ticker: WST), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on WEST PHARMACEUTICAL SERVICES's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into WEST PHARMACEUTICAL SERVICES's regulatory disclosures and financial reporting.
Robert W. McMahon, SVP & Chief Financial Officer of West Pharmaceutical Services, Inc. (WST) received equity awards reported for transactions dated 08/11/2025. The awards include 15,838 restricted stock units (RSUs) granted at a $0 price and 14,784 stock options with a $240.33 exercise price. The options become exercisable beginning 08/11/2026 and expire 08/11/2035. The first RSU award vests in three installments (4,223; 6,335; 2,112), and the second vests in four equal annual installments beginning 08/11/2026. All reported holdings are shown as direct beneficial ownership.
On 24 July 2025, West Pharmaceutical Services, Inc. (NYSE: WST) filed a Form 8-K disclosing that it has furnished (not filed) its second-quarter 2025 results under Item 2.02 and Item 7.01. The company attached two exhibits:
- 99.1 – press release announcing Q2 2025 financial results
- 99.2 – investor presentation used on the accompanying conference call
West Pharmaceutical Services, Inc. (WST) – Form 4 insider filing
On 30 June 2025, director Janet Brutschea Haugen reported an equity-based compensation transaction:
- 58 Phantom Stock Units (deferred share equivalents) were acquired (Code A) at an indicated reference price of $218.80 per unit.
- Following the award, Haugen now holds 114.06 phantom units and 1,318.4 common shares, all in direct ownership.
Phantom units convert to common stock only after the director leaves the board, indicating a long-term alignment of interests rather than an immediate open-market purchase or sale. No common-stock transactions were reported, and the filing does not reference any Rule 10b5-1 trading plan.